Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed the exchanges that its subsidiary, Optival Health Solutions Private Limited, received a four-day suspension order on its Drug License for a store located at Isakavogu Center, Chimakurthy in Andhra Pradesh's Prakasam District. The order was issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, and received on May 3, 2025. The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940. The company has quantified the potential revenue loss from this suspension at approximately Rs. 0.62 lakhs (about ₹62,000). The disclosure is being made under SEBI's Regulation 30 listing obligations.
The impact is negligible — a single store's license is suspended for just four days with a revenue loss of only around ₹62,000, which is immaterial to Medplus's overall operations and unlikely to affect the stock price.